La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

La enseñanza bíblica en profundidad de John MacArthur lleva la verdad transformadora de la Palabra de Dios a millones de personas cada día.

Title: First Biosynthetic Corneas Implanted
Category: Health News
Created: 8/26/2010 10:54:00 AM
Last Editorial Review: 8/26/2010 10:54:57 AM

REVERB features 17 audiovisual installations including new works by Es Devlin and Theaster Gates, plus Devon Turnbull's Listening Room.

The post The Vinyl Factory celebrates art and sound with immersive exhibition at 180 Studios appeared first on Fact Magazine.

Sega has sold Humankind and Endless developer Amplitude Studios to members of its internal team, announced the developer in a community post. This means the studio is now independent.

"Our studio is backed by strong and meaningful franchises and our team is committed to creating the best games possible," said Amplitude Studios founder Romain de Waubert de Genlis.

"With our extensive experiences in strategy game development and two exciting titles currently in progress, we are confident in our ability to deliver outstanding experience to players. This decision allows us to be more agile in our approach while continuing to shape the vision that has been ours from the very beginning, empowering us to push boundaries and be closer as ever of our community."

Sega in its own statement said: "Sega Europe has today announced the sale of Amplitude Studios following a management buyout from senior leaders and employees at the Parisian studio. The move will see Amplitude go back to its roots as an independent organisation and concludes the structural reforms that have been taking place in Sega’s European business.  

"The decision to part ways follows a period of close consultation between Sega Europe and Amplitude. As an independent studio once more, Amplitude will focus on its in-development projects and growing its own franchises, while Sega will continue to advance its strong and diverse stable of Japanese and Western IP. 

“Sega Europe acquired Amplitude in 2016, and together have released epic strategy titles like Endless Space 2 and Humankind, along with Endless Dungeon, the successor to 2014’s indie hit, Dungeon of the Endless.

"While Amplitude is no longer a part of the Sega family of studios, the two entities will continue to work together on the smooth transition of services and operations, ensuring minimum disruption for Amplitude employees and continuity of service for players of Amplitude games."

A life-long and avid gamer, William D'Angelo was first introduced to VGChartz in 2007. After years of supporting the site, he was brought on in 2010 as a junior analyst, working his way up to lead analyst in 2012 and taking over the hardware estimates in 2017. He has expanded his involvement in the gaming community by producing content on his own YouTube channel and Twitch channel. You can contact the author on Twitter @TrunksWD.

Full Article - https://www.vgchartz.com/article/463024/sega-sells-humankind-developer-amplitude-studios/

Kurt "CyberGuy" Knutsson shares tips and suggestions for how to get the best use out of the updated Calendar app available with the latest iOS update.

An intricate atlas of the inner lining of the uterus could help researchers better understand conditions like endometriosis, infertility and abnormal menstruation

A chemical produced by gut bacteria could be the basis for a non-invasive test for endometriosis – and mouse experiments suggest it might also help treat the condition

Back in May, Dysmantle ($9.99) from 10tons Ltd. got its final major content update on Steam. Dysmantle version 1.4.0 titled …

Continue reading "Dysmantle’s Final Major Update Is Now Live on iOS Bringing In Ark Level 4, Night Terrors, Link Towers, and Much More"

Earlier this year, Feral Interactive’s superb iOS version of Alien: Isolation (Free) was updated to change the game’s business model …

Continue reading "‘Alien: Isolation’ for Android Is Now a Free To Start Release Just Like iOS Letting Everyone Try Two Missions for Free"

Back in October last year, Feral Interactive announced that cross platform multiplayer was in the works for Company of Heroes …

Continue reading "‘Company of Heroes’ Mobile Multiplayer Beta Announced for Next Week on Android, Full Update Coming to iOS and Switch As Well"

Netflix recently announced more games coming to its service in the coming months, but an unannounced (as far as I’m …

Continue reading "‘SpongeBob: Bubble Pop’ Is a New Bust-a-Move-Like Coming to iOS and Android Through Tic Toc Games, Nickelodeon, and Netflix"

Usually, updates for premium priced ports on mobile are good to have for optimization or compatibility reasons, but Capcom’s newest …

Continue reading "Capcom Updates ‘Resident Evil 4', ‘Resident Evil Village’, and ‘Resident Evil 7’ on iOS With Online DRM"

Back in April we took a look at the trailer for Super Farming Boy from developer LemonChili. It took the …

Continue reading "‘Super Farming Boy’ Available for Pre-Order on iOS with 20% Discount, Launch Planned for Next Year"

When Square Enix released the monster collecting RPG Dragon Quest Monsters: The Dark Prince on Switch last year, I loved …

Continue reading "‘Dragon Quest Monsters: The Dark Prince’ Is Coming to iOS, Android, and Steam on September 11th With All DLC Included From the Switch Release"

Following pre-installation going live earlier in the week, HoYoverse has just released the major Genshin Impact (Free) version 5.0 “Flowers …

Continue reading "‘Genshin Impact’ Version 5.0 Update Is Now Available Worldwide on iOS, Android, PC, PS5, and More"

It looks like SNK is celebrating the 30th anniversary of the superb The King of Fighters series with a big …

Continue reading "All of SNK’s The King of Fighters ACA NeoGeo Games Are Discounted on iOS and Android, Switch Later Today"

Yesterday during the Nintendo Indie World Partner Direct whatever it is called for the double feature, Red Nexus Games’ pachinko …

Continue reading "The Huge ‘Peglin’ 1.0 Update Is Now Live on iOS, Android, and Steam Following Switch Launch Yesterday"

Last month, GungHo announced a new casual RPG for mobile in the form of Disney Pixel RPG (Free), due later …

Continue reading "Casual RPG ‘Disney Pixel RPG’ From GungHo for iOS and Android Gets New Gameplay Trailer, Listed for October 7th"

Following developer TRAGsoft bringing monster collecting game Coromon to mobile after it debuted on PC and Switch, we are getting …

Continue reading "Roguelite ‘Coromon: Rogue Planet’ in Development for Release on iOS, Android, Switch, and Steam in 2025"

Harvest Moon: Home Sweet Home has been a very interesting game to follow pre-release. I say this not only because …

Continue reading "‘Harvest Moon: Home Sweet Home’ iOS Review – A Great Start, but Needs More Work"

Balatro from developer LocalThunk and publisher Playstack is finally coming to mobile later this month on iOS, Android, and also …

Continue reading "‘Balatro’ Is Coming to Apple Arcade and Also iOS as a Standalone Premium Release Beginning September 26th"

Feral Interactive’s tease seemingly was about Total War: Empire from Creative Assembly and SEGA because the developer just announced that …

Continue reading "‘Total War: Empire’ Is Coming to iOS and Android This Fall From Feral Interactive"

Back in December, I reviewed Square Enix’s monster collecting RPG Dragon Quest Monsters: The Dark Prince on Switch. I loved …

Continue reading "‘Dragon Quest Monsters: The Dark Prince’ iOS Review – Much Better Than Switch, but Lacking in Two Ways"

One of the most useful new features in the public beta of iOS 18.2 is the capability to share the location of a lost item connected to Apple’s Find My network. Sure, you could already share an item’s location with people in your contacts list, but Apple says this could help when you have to rely on the help of a stranger.

When you choose Share Item Location in the Find My app on iPhone, iPad or Mac, you get the option to share a link that shows the location of your missing item. The link’s recipient will be able to open it on any device, and they’ll also be able to see your Apple account email and/or phone number so they can get in touch with you. You can even share the information with selected airlines. Apple has apparently worked with several carriers to integrate this feature into their systems.

Better still, air transport tech company SITA is also incorporating Share Item Location into WorldTracer, its baggage-tracing system. Apple says more than 500 airlines and ground handlers at 2,800-plus airports use it. Perfect for when I head to Portugal in just five days’ time. Yes, brag.

For now, it’s part of the public beta, so if you want the feature, you’ll have to install iOS 18.2.

— Mat Smith

The biggest tech stories you missed

• Amazon reportedly wants drivers to wear AR glasses for improved efficiency

• This Shin Megami Tensei board game features 72 intricate demon figurines

• A white Steam Deck OLED can be yours for $679

Get this delivered daily direct to your inbox. Subscribe right here!

Sonos Arc Ultra soundbar review

New tech powers a big audio upgrade.

Engadget

It’s not been a great year for Sonos, but still, here comes its latest upgraded soundbar. While the design is mostly unchanged from the Arc that debuted in 2020, there are several key changes inside the Arc Ultra that make this a better all-in-one solution. Sonos is promising better bass performance, thanks to new speaker tech debuting in the Arc Ultra, but just how good can it be? $999 worth of good?

Continue reading.

Google’s Pixel 8a is only $399, and it’s not even Black Friday

Just. Buy. This. Phone!

If you want an excellent midrange smartphone or an upgrade from that crunchy Android of yours from 2014, just get yourself the Pixel 8a, down $100 to $399. With Google’s Tensor G3 chip, the Pixel 8a supports many of the same AI features as the flagship Pixel devices. The cameras are excellent, and it has a gorgeous (and smooth) 6.1-inch 120Hz OLED display. The only caveat is… we’ve seen it drop to $380 briefly. Still, it’s a deal. We gave it a score of 90 in our review.

Continue reading.

An Overwatch: Classic event takes fans back to the beginning

A 6v6 limited-time Overwatch 2 mode starts November 12.

For the first time in over two years, Overwatch 2 players will be able to group up in teams of six for a three-week event starting today. But there’s a twist: You won’t be able to select Kiriko or Sombra or battle it out with an additional player on each side on Push maps just yet. Yes, you’ll be limited to the first 21 heroes, kitted out with their old movesets and ultimates. Did someone call for Symmetra, teleport savior? No, but they will.

Continue reading.

This article originally appeared on Engadget at https://www.engadget.com/general/the-morning-after-engadget-newsletter-121525242.html?src=rss

If you use Chrome on your iPhone, you’re about to see some features sliding over from the Android version. Google Lens will let you add text to your image searches, and you can save files and pictures directly to Google Drive and Photos. You can get “Shopping Insights” for products you’re browsing.

Chrome for iOS now lets you add words to your Google Lens visual searches, allowing you to add nuance to your query or “perform more complex and specific searches,” as Chrome Product Manager Katia Muradyan wrote in a blog post. After activating Lens by tapping the camera icon in the Chrome search bar, you can ask questions about the object you’re snapping a pic of, and it will produce corresponding results. Google says AI Overviews will also appear for some of these search results.

The feature shares some common ground with an Apple Intelligence feature for iPhone 16 owners in iOS 18.2, which is currently in beta. Visual Intelligence lets you point your camera at something and get info about it, including asking ChatGPT questions about it or searching for it on Google.

Chrome for iPhone now has a feature that lets you save a file directly to Google Drive or Google Photos, sparing you from using your phone’s internal storage. When saving files from Chrome, you’ll see a new option to save the file to Drive. Similarly, when browsing a photo you want to save, long-press on it, and you’ll see a new “Save in Google Photos” option in the context menu. Of course, the feature requires you to be signed into a Google account.

Chrome for iOS also adds a feature that pops up a mini-map when you click on an address. Look for an underlined link to specific addresses; clicking on it will take you to the mini-map without leaving the browser.

Finally, Google is adding Shopping Insights for US users. The company frames it as a way to help you find great prices on items you’re shopping for, but it’s hard to imagine this feature exists strictly from the kindness of Google's heart. Regardless, you’ll soon see a “Good Deal Now” alert in Chrome’s address bar when browsing for products for which it’s available. You’ll see details like price history / tracking and buying options if you tap it.

This article originally appeared on Engadget at https://www.engadget.com/mobile/smartphones/chrome-for-ios-now-lets-you-add-text-to-google-lens-visual-searches-170920556.html?src=rss

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these acorns that we’ve squirrelled away for you:

• Johnson & Johnson Innovative Medicines gives a peek inside its $43 billion gross-to-net bubble

• Optum Rx joins the private label biosimilar bandwagon

• Biosimilars boom for provider-administered drugs

• Fresh evidence of how copay accumulators hurt patients

Plus, words of wisdom from Cencora's soon-to-be-former CEO Steve Collis.

P.S. Join my more than 58,000 LinkedIn followers for daily links to neat stuff along with thoughtful and provocative commentary from the DCI community.

There’s still time to request an invite to the inaugural Drug Channels Leadership Forum. Attendance will be highly limited. We have already begun extending invitations, so apply now to be considered. Click here to view the full agenda.

Read more »

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Last week, the Federal Trade Commission (FTC) released the redacted version of administrative complaint against the three largest pharmacy benefit managers (PBMs). The FTC rightly calls out how the gross-to-net bubble can raise patients’ out-of-pocket costs, while also acknowledging how rebates can reduce a plan's (but not the patient’s) costs. Apparently, the FTC believes that PBMs’ customers are pretty dumb, because PBMs are able to prevent plans from “appreciating” such healthcare financing dynamics.

Section V.E. of the complaint (starting on page 23) focuses on the PBMs’ alleged unlawful conduct related to preferring high-list/high-rebate insulin products over versions with lower list prices. I thought it would therefore be fun to take the Wayback Machine to November 2021, when I wrote about this specific topic.

Below, you can review my commentary about the warped incentives behind Viatris’ dual-pricing strategy for its interchangeable biosimilar of Lantus. Much of the FTC’s description of the drug channel aligns with my commentary. But before you fist pump too hard for Ms. Khan’s FTC, you should pause to reflect on the agency’s legal theories in light of plans’ revealed preferences.

---

The Food & Drug Administration (FDA) recently approved the first interchangeable biosimilar insulin product: the insulin glargine-yfgn injection from Viatris. Read the FDA’s press release.

Alas, I’m sad to report that the warped incentives baked into the U.S. drug channel will limit the impact of this impressive breakthrough.

Viatris is being forced to launch both a high-priced and a low-priced version of the biosimilar. However, only the high-list/high-rebate, branded version will be available on Express Scripts’ largest commercial formulary. Express Scripts will block both the branded reference product and the lower-priced, unbranded—but also interchangeable—version. Meanwhile, Prime Therapeutics will place both versions on its formularies, leaving the choice up to its plan sponsor clients.

Consequently, many commercial payers will adopt the more expensive product instead of the identical—but cheaper—version. As usual, patients will be the ultimate victims of our current drug pricing system.

Below, I explain the weird economics behind this decision, highlight the negative impact on patients, and speculate on what this all could mean for biosimilars’ future. Until plan sponsors break their addiction to rebates, today’s U.S. drug channel problems will remain.
Read more »

Here on Drug Channels, we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall.

Novel transparency information reveals that this good news doesn’t always translate into savings. Below, we rely on a unique data set from Turquoise Health to examine how much four national commercial health plans—Aetna, Anthem, Cigna, and UnitedHealthcare—paid hospitals for Avastin and its two most significant biosimilar competitors.

As we demonstrate, health plans pay hospitals far above acquisition costs for biosimilars. What’s more, plans can pay hospitals more for a biosimilar than for the higher-cost reference product. The U.S. drug channel system is warping hospitals’ incentives to adopt biosimilars, while simultaneously raising costs for commercial plans.

The namesake of my alma mater once said: “Sunlight is said to be the best of disinfectants.” What would happen if we disinfected the entire channel?
Read more »

The U.S. Food and Drug Administration posted a video:

¿Qué son los biosimilares? Los biosimilares son un tipo de medicamento que se usa para tratar una variedad de afecciones, como enfermedades crónicas de la piel y los intestinos, artritis, diabetes, afecciones renales, degeneración macular y algunos tipos de cáncer. Un biosimilar es un tipo de medicamento biológico. La mayoría de los medicamentos biológicos se elaboran usando fuentes vivas, como células animales, bacterias o levaduras. Debido a que en su mayoría provienen de fuentes vivas, todos los tipos de productos biológicos tienen diferencias menores que ocurren naturalmente entre los lotes de producción. Así como los medicamentos de marca tienen versiones genéricas, los biológicos originales pueden tener biosimilares. La cuidadosa revisión de datos, estudios y pruebas por parte de la FDA ayuda a garantizar que los productos biosimilares brinden los mismos beneficios de tratamiento que el producto biológico original aprobado por la FDA. Los biosimilares pueden brindarle más acceso a tratamientos importantes y también pueden ahorrarle dinero, dependiendo de su cobertura de seguro. Se han aprobado muchos biosimilares diferentes y se esperan aún más. Para obtener más información, visite www.fda.gov/biosimilars

<p>On 19&nbsp;September 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)&nbsp;adopted a positive opinion,&nbsp;recommending the granting of marketing authorization&nbsp;for&nbsp;two aflibercept biosimilars:&nbsp;&nbsp;Sandoz’s Afqlir and Samsung Bioepis’s Opuviz.&nbsp;These products are biosimilars of the reference product Eylea, developed by Regeneron and Bayer.</p>

<p>The US Food and Drug Administration (FDA) granted approval for two&nbsp;biosimilars, Formycon’s FYB202/Otulfi (ustekinumab-aauz) and Samsung Bioepis’ Soliris biosimilar, Epysqli (eculizumab-aagh), on 27 September and 22 July 2024, respectively. FYB202/Otulfi, a biosimilar referencing&nbsp;Johnson &amp; Johnson’s Stelara, while Epysqli is a biosimilar referencing Alexion’s Soliris.</p>

<p> <b>BIOSIMILAR RED TAPE ELIMINATION ACT (S2305):</b><br /> <b><i>Weakening FDA Regulatory Standards for Biosimilars, Undermining Physician Confidence and Jeopardizing Patient Health</i></b><br /><b>31 October 2024&nbsp;|&nbsp;</b><b><a href="https://youtu.be/X6-dYZ7fjhM" target="_blank">WATCH REPLAY</a></b></p>

<p>In October 2024, China based Bio-Thera Solutions&nbsp;(Bio-Thera)&nbsp;and Hungary’s Gedeon Richter announced they have reached an exclusive commercialization and license agreement for BAT2206, a biosimilar candidate to&nbsp;Johnson &amp; Johnson’s Stelara (ustekinumab).</p>

<p>The European Commission (EC) granted marketing authorization for<b>&nbsp;</b>three ustekinumab biosimilars<b>:&nbsp;</b>Samsung Bioepis’ Eksunbi on 12 September 2024; Formycon’s Fymskina, and Fresenius Kabi’s&nbsp;Otulfi on 25 September 2024.</p>

<p> <b>Abstract</b><br />CinnaGen, the largest biopharmaceutical company in the MENA region, is a leader in developing follow-on biologicals/biosimilars. Dr&nbsp;Haleh Hamedifar, Chairperson of CinnaGen, spoke to GaBI<i>&nbsp;</i>(Generics and Biosimilars Initiative) about the company’s strategic focus, which includes expanding its product portfolio, entering highly regulated global markets, and advancing affordable treatments for conditions such as multiple sclerosis and&nbsp;immunological diseases—transforming healthcare in underserved regions.</p><p><b>Keywords</b>: Biosimilars, clinical development, commercialization, MENA</p>

Sweat: We all do it. It plays an essential role in controlling body temperature by cooling the skin through evaporation. But it can also carry salts and other molecules out of the body in the process. In medieval Europe, people would lick babies; if the skin was salty, they knew that serious illness was likely. (We now know that salty skin can be an indicator for cystic fibrosis.)

Scientists continue to study how the materials in sweat can reveal details about an individual’s health, but often they must rely on gathering samples from subjects during strenuous exercise in order to get samples that are sufficiently large for analysis.

Now researchers in China have developed a wearable sensor system that can collect and process small amounts of sweat while providing continuous detection. They have named the design a “skin-interfaced intelligent graphene nanoelectronic” patch, or SIGN for short. The researchers, who described their work in a paper published in Advanced Functional Materials, did not respond to IEEE Spectrum’s interview requests.

The SIGN sensor patch relies on three separate components to accomplish its task. First, the sweat must be transported from the skin into microfluidic chambers. Next, a special membrane removes impurities from the fluid. Finally, this liquid is delivered to a bioreceptor that can be tuned to detect different metabolites.

The transport system relies on a combination of hydrophilic (water-attracting) and hydrophobic (water-repelling) materials. This system can move aqueous solutions along microchannels, even against gravity. This makes it possible to transport small samples with precision, regardless of the device’s orientation.

The fluid is transported to a Janus membrane, where impurities are blocked. This means that the sample that reaches the sensor is more likely to produce accurate results.

Finally, the purified sweat arrives at a flexible biosensor. This graphene sensor is activated by enzymes designed to detect the desired biomarker. The result is a transistor that can accurately measure the amount of the biomarker in the sample.

At its center, the system has a membrane that removes impurities from sweat and a biosensor that detects biomarkers.Harbin Institute of Technology/Shenyang Aerospace University

One interesting feature of the SIGN patch is that it can provide continuous measurements. The researchers tested the device through multiple cycles of samples with known concentrations of a target biomarker, and it was about as accurate after five cycles as it was after just one. This result suggests that it could be worn over an extended period without having to be replaced.

Continuous measurements can provide useful longitudinal data. However, Tess Skyrme, a senior technology analyst at the research firm IDTechEx, points out that continuous devices can have very different sampling rates. “Overall, the right balance of efficient, comfortable, and granular data collection is necessary to disrupt the market,” she says, noting that devices also need to optimize “battery life, calibration, and data accuracy.”

The researchers have focused on lactate—a metabolite that can be used to assess a person’s levels of exercise and fatigue—as the initial biomarker to be detected. This function is of particular interest to athletes, but it can also be used to monitor the health status of workers in jobs that require strenuous physical activity, especially in hazardous or extreme working conditions.

Not all experts are convinced that biomarkers in sweat can provide accurate health data. Jason Heikenfeld, director of the Novel Device Lab at the University of Cincinnati, has pivoted his research on wearable biosensing from sweat to the interstitial fluid between blood vessels and cells. “Sweat glucose and lactate are way inferior to measures that can be made in interstitial fluid with devices like glucose monitors,” he tells Spectrum.

The researchers also developed a package to house the sensor. It’s designed to minimize power consumption, using a low-power microcontroller, and it includes a Bluetooth communications chip to transmit data wirelessly from the SIGN patch. The initial design provides for 2 hours of continuous use without charging, or up to 20 hours in standby mode.

CDMO Avid Bioservices is being acquired by the private equity firms GHO Capital Partners and Ampersand Capital Partners. Avid specializes in manufacturing biologic products for companies at all stages of development.

The post Private Equity Is Picking Up Biologics CDMO Avid Bioservices in $1.1B Acquisition appeared first on MedCity News.